Trials / Not Yet Recruiting

Not Yet RecruitingNCT07464210

Nemtabrutinib, Bortezomib, and Rituximab for WM

Nemtabrutinib, Bortezomib, and Rituximab for the Treatment of Waldenstrom's Macroglobulinemia (NEBULA)

Status: Not Yet Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 19 (estimated)

Sponsor: Seoul National University Hospital · Academic / Other
Sex: All
Age: 19 Years
Healthy volunteers: Not accepted

Summary

This is a phase II (2 parts), open-label, single arm, multicenter study to evaluate the efficacy and safety of nemtabrutinib in combination with bortezomib and rituximab

Conditions

Waldenstrom Macroglobulinemia

Interventions

Type	Name	Description
DRUG	NEBULA	Nemtabrutinib + Bortezomib + Rituximab

Timeline

Start date: 2026-06-01
Primary completion: 2029-08-01
Completion: 2030-08-01
First posted: 2026-03-11
Last updated: 2026-03-11

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT07464210. Inclusion in this directory is not an endorsement.